Delhi HC: Alphabets Can't Be Trademarked; Alkem Loses 'A TO Z' Pharma Plea

LAWCOURT
Whalesbook Logo
AuthorIshaan Verma|Published at:
Delhi HC: Alphabets Can't Be Trademarked; Alkem Loses 'A TO Z' Pharma Plea
Overview

The Delhi High Court has ruled that English alphabets cannot be monopolized through trademark law, rejecting Alkem Laboratories' bid to exclusively use the 'A TO Z' mark for its pharmaceutical products. Justice Tejas Karia found the mark descriptive, preventing Alkem from claiming exclusivity. The ruling allows Prevego Healthcare to continue using its 'Multivein AZ' brand, citing significant differences and Alkem's failure to disclose prior trademark issues.

Ruling on Descriptive Marks

The Delhi High Court has delivered a significant judgment stating that English alphabets are not eligible for trademark exclusivity. Justice Tejas Karia's bench refused interim protection to Alkem Laboratories Limited for its 'A TO Z' mark, asserting that such marks are descriptive and cannot be monopolized by a single entity. The court found Alkem's claim over the letters 'A' and 'Z' unsupported by trademark law.

Competitor's Branding Upheld

The ruling came as Alkem Laboratories sued Prevego Healthcare and Research Pvt Ltd over the use of 'AZ' in Prevego's 'Multivein AZ' multivitamin product. Alkem argued that Prevego's branding infringed upon its 'A to Z' and 'A to Z-NS' brands, which it has used since 1998. However, the court agreed with Prevego's defense that 'A to Z' is a common phrase signifying comprehensiveness and lacks distinctiveness for exclusive trademark protection. Prevego also highlighted Alkem's lack of a registered word-mark for 'A to Z' in the relevant class.

Non-Disclosure and Infringement Claims

Further weakening Alkem's position, the court criticized the company for failing to disclose previous withdrawn, abandoned, or opposed trademark applications for 'A TO Z' in Class 5. This non-disclosure disqualified Alkem from receiving equitable relief. The court also dismissed Alkem's claims of copyright infringement. Consequently, an earlier ex parte injunction favouring Alkem was vacated, permitting Prevego to continue marketing 'Multivein AZ'.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.